SI-BONE SIBN
SI-BONE FY 2022: revenue $106.4M, up 18%; diluted EPS −$1.79
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0001459839-23-000020
Key figures from this report
These are the numbers SI-BONE reported for the year ended Dec 31, 2022, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Revenue$106.4M+18% from $90.2M in FY 202110-K income statement, on EDGAR
- Net income−$61.3MAgainst −$56.6M in FY 202110-K income statement, on EDGAR
- Diluted EPS−$1.79Against −$1.71 in FY 202110-K income statement, on EDGAR
- Cash and cash equivalents$20.7M−67% from $63.4M in FY 2021Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
- Cash from operations−$41.7MAgainst −$39.5M in FY 202110-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.
- Biolife Solutions BLFS public float $845M, Jun 30, 2025
- Embecta EMBC public float $732M, Mar 31, 2025, over 18 months old
- Mimedx Group MDXG public float $719M, Jun 30, 2025
- Heartflow HTFL
- Integra Lifesciences Holdings IART public float $925M, Jun 30, 2025
